The company's S-1 lays the groundwork for what is widely expected to be one of the largest initial public offerings of the year, second only to Uber's IPO in May. It's also...Technologyread more
Fraud investigator Harry Markopolos' accusations extended beyond GE's management to actuaries, auditors and analysts who he claims overlooked billions in liabilities.Marketsread more
Trump's tweet comes a day after Apple put out a press release describing the money it spends on U.S.-based suppliers and vendors.Technologyread more
CNBC combed through Wall Street research to see which stocks are still a buy after their earnings reports.Marketsread more
President Donald Trump held a call on Wednesday with the CEOs of three major U.S. banks, according to people with knowledge of the situation.Marketsread more
Despite aggressive strides, Waymo needs one thing before their self-driving cars become a seriously useful transportation system: people. We talked to the ones closest to it.Technologyread more
Scientists say the smoke plumes, filled with megatons of tiny, harmful particles, could travel to other areas of the world and cause serious respiratory problems for people.Weather & Natural Disastersread more
Some Weight Watchers loyalists applaud Kurbo by WW. But nutritionists worry Kurbo promotes an unhealthy relationship with food during an especially impressionable time.Health and Scienceread more
Benefits from what President Trump called "the biggest reform of all time" to the tax code have dwindled to a faint breeze just 20 months after its enactment, writes John...Politicsread more
Epstein, 66, was found in his cell in Manhattan federal lockup Saturday morning and transferred to a nearby hospital, where he was subsequently pronounced dead.Politicsread more
Air travelers faced delays at U.S. airports on Friday afternoon after a computer issue snarled processing of international arrivals.Airlinesread more
(Recasts story, adds details, background on EpiPen shortages)
July 29 (Reuters) - Mylan NV's planned merger with Pfizer Inc's off-patent branded drugs business may have boosted its share price on Monday, but one of its most pressing problems remains: shortages of its flagship EpiPen emergency allergy treatment.
For the past year, Mylan has been struggling to address an ongoing EpiPen shortage that could potentially worsen as thousands of school children with allergies need to restock EpiPen supplies ahead of the school year.
Now, the planned tie-up will bring together two businesses that have long collaborated on making EpiPens. For years, Pfizer has manufactured EpiPen on Mylan's behalf through its Meridian Medical Technologies unit.
It was not yet clear if the combination will help ease the shortages by simplifying the company's complex manufacturing processes.
Although Meridian will not be merged with Mylan as part of the transaction announced on Monday, the companies were in talks to transfer Meridian to the newly created generics business, a Pfizer spokeswoman said.
The discussions are still ongoing and there is no guarantee that a deal will be reached, but the parties are aiming to reach a final decision before the close of the larger Pfizer-Mylan deal in 2020, Pfizer said.
"Weve had some conversations with Mylan about that potentially transferring to Mylan as a supplement to the existing transaction, but nothing has been finalized to date yet," Frank D'Amelio, Pfizer's chief financial officer told Reuters.
If the company is transferred to the new Mylan-Pfizer spinoff, it could potentially help streamline a fix to the manufacturing issues that have led to shortages.
Over the long term, having all EpiPen operations under one unified company would reduce complexity, " said Ashtyn Evans, an Edward Jones analyst.
Meridian, which produces all EpiPens sold globally at a single plant near St. Louis, has been hit by a series of manufacturing problems since at least 2018 that resulted in shortages in the United States and elsewhere. The company said in early July it anticipates further supply shortages over the coming months.
Canada's national health agency said earlier this month it continued to experience EpiPen shortages as well.
Mylan, a generic drugmaker that came under fire from mothers and politicians over steep EpiPen price hikes, has been facing new competition for its emergency allergy treatment.
Teva Pharmaceuticals Industries has launched its own EpiPen generic, and other companies including Novartis AG , Kaleo Inc and Amneal Pharmaceuticals Inc also are in the market with rival products. (Reporting by Carl O'Donnell and Tamara Manias in Bengalaru; editing by Marguerita Choy and Bill Berkrot)